Press "Enter" to skip to content

Tag: XBB.1.5

Fall COVID-19 vaccine cut illness risk by half overall

The fall COVID-19 vaccine cut the risk of COVID-19 illness by about half overall, and by 67 per cent for those with a previous infection, according to new research from the Canadian network that has long tracked the performance of the annual flu shot.

This is the first time the Canadian Sentinel Practitioner Surveillance Network, which is comprised of hundreds of primary care providers in British Columbia, Alberta, Ontario and Quebec, produced mid-season estimates of the effectiveness of immunization against COVID-19.

Comments closed

Canadian data show moderate to good vaccine efficacy against COVID, flu

The Canadian Sentinel Practitioner Surveillance Network (SPSN) data reveal mid-season vaccine effectiveness (VE) against the SARS-CoV-2 Omicron XBB.1.5 variant of 47% against medically attended outpatient COVID-19 and 67% among previously infected people.

The same test-negative case-control study reports that the flu vaccine is 63% effective against medically attended outpatient infection with the influenza A H1N1 strain and 40% against H3N2.

The researchers enrolled patients with new or worsening cough that is characteristic of acute respiratory illness (ARI) who sought care within 7 days of symptom onset from community-based sentinel practitioners in Alberta, British Columbia (BC), Ontario, or Quebec.

Comments closed

New estimates show latest COVID vaccine cuts risk of symptomatic infection

Today in Morbidity and Mortality Weekly Report, researchers published findings showing adults who received an updated 2023-24 COVID-19 vaccine were 54% less likely to have symptomatic infection than those who didn’t, and the vaccine was found to protect against JN.1 and other circulating variants.

This is one of the first studies to update 2023-24 COVID vaccine effectiveness (VE) data. The monovalent (single-strain) booster vaccine derived from XBB.1.5 was approved for use in all Americans 6 months and older on September 12, 2023, but uptake has been low. Moreover, the XBB strains of the virus, which the vaccine was based on, are no longer the dominant strains in the United States, having been replaced by JN.1 in December 2023.

Comments closed

Older, immunocompromised people may get COVID-19 vaccine dose in spring, NACI says

Canada’s National Advisory Committee on Immunization says some groups of people vulnerable to severe illness from COVID-19 should be eligible for another dose of vaccine in the spring.

The recommendation issued Friday says people aged 65 and older, residents of long-term care homes and seniors living in other congregate settings may get another shot of the vaccine targeted to the XBB.1.5 variant.

It also says children and adults aged six months and older who are moderately to severely immunocompromised due to an underlying condition may also get the booster.

Comments closed

Updated COVID vaccine 71% effective against hospitalization for older adults

The estimated effectiveness of the updated COVID-19 vaccine among people aged 60 and older in the Netherlands was 70.7% against hospitalization and 73.3% against intensive care unit (ICU) admission in fall and early winter 2023, according to a study published yesterday in Eurosurveillance.

Researchers at the National Institute for Public Health and the Environment and University Medical Center Utrecht parsed data on hospitalizations with admission dates from October to December to estimate the effectiveness of the XBB.1.5 Pfizer/BioNTech COVID-19 vaccine among recipients of at least one previous vaccination. The study included 2,050 hospitalized adults aged 60 and older, 14.4% of whom had received the 2023 COVID-19 vaccine.

Comments closed

Is the Novavax COVID Vaccine Better than mRNA Vaccines? What We Know So Far

As the updated COVID vaccines roll out around the country, one more competitor has joined the mix. In early October the U.S. Food and Drug Administration authorized a new booster shot made by the company Novavax. Like the mRNA-based Pfizer and Moderna shots, it targets a SARS-CoV-2 variant, XBB.1.5, which is a descendant of Omicron.

Comments closed

Appointments for new Moderna COVID-19 vaccine now available in N.S.

Appointments are now available in Nova Scotia for a new monovalent Moderna COVID-19 vaccine, which the provincial government says provides the best protection against the latest strain of the virus.

Comments closed

Health Canada authorizes updated Pfizer-BioNTech COVID vaccine

Health Canada has authorized Pfizer-BioNTech’s updated COVID-19 vaccine for people six months and older.

The mRNA vaccine targets the Omicron XBB.1.5 subvariant that is circulating in Canada.

Comments closed

Health Canada approves Moderna’s updated COVID-19 vaccine

Health Canada has approved Moderna’s updated COVID-19 vaccine for all Canadians who are six months of age and older — while two other options for fall shots remain in the regulatory pipeline.

Comments closed

Moderna’s updated COVID vaccine targeting XBB.1.5 approved in Canada

Health Canada has given the green light to an eagerly anticipated fall COVID-19 booster shot in hopes of bolstering the nation’s defence against the virus as the fall season approaches.

Comments closed

Santé Canada approuve la mise à jour du vaccin de Moderna contre la COVID-19

Health Canada announced on Tuesday that it is authorizing the use of an updated Moderna COVID-19 vaccine for all Canadians over the age of six months, at a time when federal public health has recommended that Canadians roll up their sleeves and return for vaccination.

Comments closed

Will updated COVID vaccines work against latest variant? Canadian scientists monitor global research

Health Canada is currently reviewing applications for Moderna and Pfizer-BioNTech’s new mRNA vaccines, developed against the dominant XBB.1.5 variant ahead of a vaccination campaign set for the fall.

Comments closed